Wystrychowski Wojciech, McAllister Todd N, Zagalski Krzysztof, Dusserre Nathalie, Cierpka Lech, L'Heureux Nicolas
Department of General, Vascular, and Transplant Surgery, Medical University of Silesia, Katowice, Poland.
Cytograft Tissue Engineering, Inc, Novato, Calif.
J Vasc Surg. 2014 Nov;60(5):1353-1357. doi: 10.1016/j.jvs.2013.08.018. Epub 2013 Oct 5.
An arteriovenous fistula is the current gold standard for chronic hemodialysis access. Tunneled catheters or synthetic grafts have poorer outcomes and much higher risks of infection. This report presents the first clinical use of a completely biological, allogeneic, nonliving, and human tissue-engineered vascular graft. Tissue-engineered vascular grafts built from allogeneic fibroblasts were implanted as shunts in three hemodialysis patients. The tissue-engineered vascular graft was stored for 9 months, without loss of mechanical strength. Implanted grafts showed no signs of degradation or dilation, with time points up to 11 months. Results of panel-reactive antibody and cross-reactivity tests showed no evidence of immune responses.
动静脉内瘘是目前慢性血液透析通路的金标准。隧道式导管或合成移植物的治疗效果较差，感染风险高得多。本报告介绍了一种完全生物性、同种异体、无生命的人体组织工程血管移植物的首次临床应用。用同种异体成纤维细胞构建的组织工程血管移植物作为分流管植入三名血液透析患者体内。该组织工程血管移植物保存了9个月，机械强度未丧失。植入的移植物在长达11个月的时间点内没有出现降解或扩张的迹象。群体反应性抗体和交叉反应测试结果显示没有免疫反应的迹象。
